May 27, 2020
Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder
Mar 26, 2020
European Medicines Agency Accepts Arvelle Therapeutics' Marketing Authorization Application for Cenobamate for the Adjunctive Treatment of Focal-Onset Seizures in Adults
Nov 25, 2019
UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.
May 20, 2019
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
Mar 06, 2019
Okayama University Research: Inflammation in the Brain Enhances the Side-effects of Hypnotic Medication
Nov 30, 2018
UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership
Nov 29, 2018
Aquestive Therapeutics Launches SYMPAZAN(TM) (clobazam) Oral Film with Widespread U.S. Availability
Nov 02, 2018
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN(TM) (clobazam) Oral Film
Oct 23, 2018
Upsher-Smith Launches Generic Version Of Onfi® (clobazam), CIV In Tablet And Oral Suspension Dosage Forms
Oct 23, 2018
Breckenridge Announces Final Approval of its ANDA for Clobazam Tablets (Generic for Onfi®)
Oct 23, 2018
Amneal Announces Approval and Launch of Clobazam Tablets and Clobazam Oral Suspension
Aug 31, 2018
Aquestive Therapeutics Announces Tentative FDA Approval for Sympazan(TM) (clobazam) Oral Film
Aug 23, 2018
FDA approves DIACOMIT (Stiripentol) for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam
May 14, 2018
UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients